

Resource Summary Report

Generated by [dkNET](#) on Sep 23, 2026

MOLM-14

RRID:CVCL_7916

Type: Cell Line

Proper Citation

RRID:CVCL_7916

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7916

Proper Citation: RRID:CVCL_7916

Description: Cell line MOLM-14 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute myeloid leukemia

Defining Citation: [PMID:9305600](#), [PMID:12529668](#), [PMID:21552520](#)

Comments: Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MOLM-14

Synonyms: Molm-14, Molm 14, Molm14, MOLM14

Cross References: BTO:BTO_0005720, EFO:EFO_0022446, Cell_Model_Passport:SIDM00436, ChEMBL-Cells:ChEMBL3706571, ChEMBL-Targets:ChEMBL3706570, Cosmic:787418, Cosmic:1150898, Cosmic:1281333, DepMap:ACH-001574, DSMZ:ACC-777, DSMZCellDive:ACC-777, GEO:GSM2037134, GEO:GSM2037135, GEO:GSM3145574, GEO:GSM3145724, JCRB:JCRB1812, Lonza:978, PubChem_Cell_line:CVCL_7916, Wikidata:Q54906323

ID: CVCL_7916

Record Creation Time: 20220427T220816+0000

Ratings and Alerts

No rating or validation information has been found for MOLM-14.

No alerts have been found for MOLM-14.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hofstetter M, et al. (2026) Enhancement of CD117-Targeted Bispecific T-cell Engagement by CD33-Targeted Bispecific T-cell Costimulation in Acute Myeloid Leukemia. Cancer research communications, 6(4), 946.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. Cell chemical biology, 33(1), 59.

Pyun WY, et al. (2026) Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. Cancer research, 86(5), 1194.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. Cancer discovery.

Price HE, et al. (2026) Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. Molecular cancer therapeutics, 25(5), 727.

Han C, et al. (2025) An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance. Blood cancer discovery, 6(5), 464.

Biederstädt A, et al. (2025) Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer cell.

Leesang TE, et al. (2025) Retinoic acid and ascorbate synergize to suppress myeloid leukemia via TET2 activation. Cell reports, 44(10), 116379.

Sonowal H, et al. (2025) Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia. Cancer research communications, 5(1), 74.

Peled A, et al. (2025) BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway. Research square.

Hlavaty SI, et al. (2024) ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis. *Cell reports*, 43(12), 114988.

Lee JK, et al. (2024) Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3 β Activation and c-Myc and Mcl-1 Proteasomal Degradation. *Cancer research communications*, 4(2), 431.

Coleman DJL, et al. (2024) Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1. *iScience*, 27(4), 109576.

Zhu J, et al. (2024) The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia. *The FEBS journal*.

Park SM, et al. (2023) Dual IKZF2 and CK1 γ degrader targets acute myeloid leukemia cells. *Cancer cell*, 41(4), 726.

Nguyen TD, et al. (2023) Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid-Antibody-Drug Conjugates. *Molecular cancer therapeutics*, 22(11), 1332.

Popescu B, et al. (2023) Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. *Cell reports. Medicine*, 4(11), 101290.

Chen EC, et al. (2023) Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(5), 878.

Maru B, et al. (2023) PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy. *Cell reports. Medicine*, 4(9), 101191.

Galán-Díez M, et al. (2022) Subversion of Serotonin Receptor Signaling in Osteoblasts by Kynurenine Drives Acute Myeloid Leukemia. *Cancer discovery*, 12(4), 1106.